Biohaven’s Nurtec ODT and AbbVie’s Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights

Growth of newer market entrants resulting in relatively flat projected share for Eli Lilly’s Emgality, Teva’s Ajovy, and Amgen’s Aimovig EXTON, Pa., June 10, 2022 /PRNewswire/ — According to the latest deep dive report included in Spherix’s Launch Dynamix™: Qulipta for Migraine…